PATENT CLAIM ANALYSIS

Application Number: 15877436
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to a pharmaceutical composition comprising PD-1 antagonist and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of cancer. The invention also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.

Claim (Index 55):
The pharmaceutical combination for use according to  claim 41 , wherein the PD-1 antibody molecule and Compound A, or a pharmaceutically acceptable salt thereof, are administered independently at the same time or separately within time intervals, optionally followed by one or more cycles of repeat dosing; or\n wherein the PD-1 antibody molecule and Compound A, or a pharmaceutically acceptable salt thereof, are administered independently at the same time or separately within time intervals, followed by one or more cycles of repeat dosing and wherein each cycle is followed by a drug holiday period.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.79167
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14604415', '15751140', '14881888', '15595618', '14610837']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7594490738612728
- 35 USC 102 Novelty (BERT): 0.5299869504683513
- Combined Prediction Score: 0.7365028615219806
- Mean Citation Score: 334.040494
- Max Citation Score: 353.73898
- Similarity Product: 204.45139261219623

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test